[go: up one dir, main page]

CL2020001097A1 - Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. - Google Patents

Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.

Info

Publication number
CL2020001097A1
CL2020001097A1 CL2020001097A CL2020001097A CL2020001097A1 CL 2020001097 A1 CL2020001097 A1 CL 2020001097A1 CL 2020001097 A CL2020001097 A CL 2020001097A CL 2020001097 A CL2020001097 A CL 2020001097A CL 2020001097 A1 CL2020001097 A1 CL 2020001097A1
Authority
CL
Chile
Prior art keywords
pyridinecarbonyl
derivatives
compounds
therapeutic uses
procedures
Prior art date
Application number
CL2020001097A
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Keenan Lana Louise Smith
Michael D Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Hydra Biosciences Llc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences Llc, Boehringer Ingelheim Int filed Critical Hydra Biosciences Llc
Publication of CL2020001097A1 publication Critical patent/CL2020001097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA (I), Y A SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R1 A R7 ,A, Y Y L SON TAL COMO SE DEFINEN EN EL PRESENTE DOCUMENTO. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS, A MÉTODOS DE USO DE ESTOS COMPUESTOS EN EL TRATAMIENTO DE DIVERSAS ENFERMEDADES Y TRASTORNOS, PROCEDIMIENTOS PARA PREPARAR ESTOS COMPUESTOS Y PRODUCTOS INTERMEDIOS ÚTILES EN ESTOS PROCEDIMIENTOS.
CL2020001097A 2017-10-27 2020-04-23 Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. CL2020001097A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
CL2020001097A1 true CL2020001097A1 (es) 2020-08-28

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020001097A CL2020001097A1 (es) 2017-10-27 2020-04-23 Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CL2020002562A CL2020002562A1 (es) 2017-10-27 2020-10-02 (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002562A CL2020002562A1 (es) 2017-10-27 2020-10-02 (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.

Country Status (30)

Country Link
US (4) US10889568B2 (es)
EP (2) EP3786160B1 (es)
JP (2) JP7217273B6 (es)
KR (2) KR20200125758A (es)
CN (1) CN111527078B (es)
AU (2) AU2018355743B2 (es)
BR (1) BR112020007818A2 (es)
CA (1) CA3078769A1 (es)
CL (2) CL2020001097A1 (es)
CY (1) CY1126109T1 (es)
DK (2) DK3700902T3 (es)
ES (2) ES2924933T3 (es)
FI (1) FI3700902T3 (es)
HR (2) HRP20230502T1 (es)
HU (2) HUE062460T2 (es)
IL (2) IL274039B (es)
LT (2) LT3700902T (es)
MX (1) MX387232B (es)
PE (1) PE20210154A1 (es)
PH (1) PH12020550503A1 (es)
PL (2) PL3786160T3 (es)
PT (2) PT3786160T (es)
RS (2) RS64271B1 (es)
SA (1) SA520411843B1 (es)
SG (2) SG11202003367TA (es)
SI (2) SI3700902T1 (es)
TW (2) TWI780511B (es)
UA (1) UA128474C2 (es)
WO (1) WO2019081637A1 (es)
ZA (1) ZA202002372B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49699E1 (en) 2017-10-27 2023-10-17 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158572A1 (en) * 2018-02-15 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
CN111868055B (zh) * 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
EP3959206A1 (en) 2019-04-12 2022-03-02 Boehringer Ingelheim International GmbH Inhibitors of trpc6
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
US20230137816A1 (en) 2020-02-11 2023-05-04 Deutsches Herzzentrum Muenchen Des Freistaates Bayern Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
AR121846A1 (es) 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
JP7502462B2 (ja) * 2020-04-16 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器状態を処置するためのｔｒｐｃ６阻害剤
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
CN118055765A (zh) 2021-10-15 2024-05-17 勃林格殷格翰国际有限公司 用于治疗脓毒症的trpc6抑制性化合物
JP2025023360A (ja) * 2021-12-06 2025-02-17 国立大学法人 熊本大学 Ｔｒｐｃ６の発現を抑制する方法
WO2025042707A1 (en) 2023-08-18 2025-02-27 Boehringer Ingelheim International Gmbh Inhibitors of trpc6 for treating focal segmental glomerulosclerosis

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
WO2002008221A2 (en) 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
RU2285002C2 (ru) * 2001-06-15 2006-10-10 Астеллас Фарма Инк. Производное пиридина и фармацевтическая композиция на его основе
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
EP1809626A2 (en) 2004-10-13 2007-07-25 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
DE102005044814A1 (de) 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PE20070795A1 (es) 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
CN101426777A (zh) 2005-12-21 2009-05-06 先灵公司 用作组胺h3拮抗剂的苯氧基哌啶及其类似物
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
MY156814A (en) 2007-03-15 2016-03-31 Novartis Ag Organic compounds and their uses
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
WO2010080357A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
WO2011044001A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
PH12012500911A1 (en) 2009-11-18 2012-11-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
TWI525090B (zh) 2010-04-27 2016-03-11 Mitsubishi Tanabe Pharma Corp Novel amide derivatives and their use as pharmaceuticals
MX2012013130A (es) 2010-05-13 2013-04-11 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.
JP5889895B2 (ja) 2010-07-29 2016-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｍｐｋ活性化複素環化合物およびその使用方法
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
EP2773199B1 (en) 2011-10-31 2019-04-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
ES2804271T3 (es) 2013-05-27 2021-02-05 Hoffmann La Roche Nuevos compuestos de 3,4-dihidro-2H-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CN112920180A (zh) 2014-01-06 2021-06-08 理森制药股份公司 谷氨酰胺酶抑制剂
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CA3028815A1 (en) 2016-06-20 2017-12-28 Rutgers, The State University Of New Jersey Therapeutic compounds
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
JPWO2018159827A1 (ja) 2017-03-03 2020-01-09 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
WO2018170225A1 (en) 2017-03-15 2018-09-20 Athenex, Inc. Biaryl piperidine amide compounds and methods of use thereof
HRP20230502T1 (hr) 2017-10-27 2023-09-15 Boehringer Ingelheim International Gmbh Inhibitori trpc6
WO2019099582A1 (en) * 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors
WO2019158572A1 (en) 2018-02-15 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
CN111868055B (zh) 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49699E1 (en) 2017-10-27 2023-10-17 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6

Also Published As

Publication number Publication date
LT3700902T (lt) 2023-06-26
UA128474C2 (uk) 2024-07-24
RS64271B1 (sr) 2023-07-31
HUE062460T2 (hu) 2023-11-28
WO2019081637A1 (en) 2019-05-02
ES2924933T3 (es) 2022-10-11
CA3078769A1 (en) 2019-05-02
TW201930294A (zh) 2019-08-01
KR20200125758A (ko) 2020-11-04
BR112020007818A2 (pt) 2020-10-20
JP2021008503A (ja) 2021-01-28
US10889568B2 (en) 2021-01-12
PL3786160T3 (pl) 2022-10-24
FI3700902T3 (fi) 2023-05-25
PT3700902T (pt) 2023-05-30
EP3786160B1 (en) 2022-07-13
ZA202002372B (en) 2023-10-25
EP3700902B1 (en) 2023-03-08
SG10202011632RA (en) 2021-01-28
PL3700902T3 (pl) 2023-09-04
IL274039B (en) 2021-08-31
IL274039A (en) 2020-06-30
PE20210154A1 (es) 2021-01-26
US20190169168A1 (en) 2019-06-06
SI3700902T1 (sl) 2023-10-30
CN111527078B (zh) 2023-06-02
AU2018355743A1 (en) 2020-05-14
USRE49699E1 (en) 2023-10-17
TWI780511B (zh) 2022-10-11
HRP20220991T1 (hr) 2022-11-11
MX387232B (es) 2025-03-18
IL277493A (en) 2020-11-30
TWI780246B (zh) 2022-10-11
JP6979502B2 (ja) 2021-12-15
PT3786160T (pt) 2022-08-19
CY1126109T1 (el) 2023-11-15
PH12020550503A1 (en) 2021-03-22
KR102724066B1 (ko) 2024-10-30
US20210163449A1 (en) 2021-06-03
HRP20230502T1 (hr) 2023-09-15
LT3786160T (lt) 2022-09-26
KR20200095467A (ko) 2020-08-10
JP7217273B2 (ja) 2023-02-02
US10800757B2 (en) 2020-10-13
RS63535B1 (sr) 2022-09-30
EP3786160A1 (en) 2021-03-03
CL2020002562A1 (es) 2021-01-15
EP3700902B8 (en) 2023-08-02
IL277493B (en) 2022-02-01
JP2021500390A (ja) 2021-01-07
HUE059450T2 (hu) 2022-11-28
CN111527078A (zh) 2020-08-11
EP3700902A1 (en) 2020-09-02
AU2018355743B2 (en) 2022-04-14
SA520411843B1 (ar) 2024-01-27
JP7217273B6 (ja) 2024-02-08
AU2020250185A1 (en) 2020-11-12
MX2020004283A (es) 2021-10-21
SG11202003367TA (en) 2020-05-28
US20190169167A1 (en) 2019-06-06
DK3700902T3 (en) 2023-05-22
TW202120494A (zh) 2021-06-01
DK3786160T3 (da) 2022-08-22
AU2020250185B2 (en) 2022-04-14
SI3786160T1 (sl) 2022-11-30
ES2946274T3 (es) 2023-07-14

Similar Documents

Publication Publication Date Title
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY36124A (es) Derivados de carboxamida
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
MX2019004484A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
UY36123A (es) Derivados de carboxamida
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις